跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT01546038
NCT01546038已完成2 期

A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME

Pfizer78 个研究点 分布在 1 个国家目标入组 255 人开始时间: 2012年6月27日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Pfizer
入组人数
255
试验地点
78
主要终点
Number of Participants With Dose-limiting Toxicities (DLTs) at Phase 1B
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these diseases.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Patients with AML or RAEB 2 High Risk MDS who are newly diagnosed according to the WHO 2008 Classification and previously untreated.
  • •Patients with AML (arising from an antecedent hematologic disease [AHD]) or MDS who may have had one prior regimen with commercially available agents for the treatment of their prior hematologic disease. The patients may not have had a prior therapy for their AML.
  • •AML patients include de novo AML, AML evolving from MDS or other AHD and AML after previous cytotoxic therapy or radiation (secondary AML)
  • •For a diagnosis of AML, a bone marrow blast count of 20% or more is required.
  • •For a diagnosis of high-risk Myelodysplastic Syndrome RAEB 2 the patient must have 10-19% bone marrow blasts
  • •Adequate Organ Function
  • •ECOG Performance Status 0, 1, or 2

排除标准

  • •AML M3 Acute Promyelocytic Leukemia (APL) or patients with a t(9:22) cytogenetic translocation.
  • •Patients with known active uncontrolled central nervous system (CNS) leukemia.

研究组 & 干预措施

Arm A (Phase 1B)

Experimental

PF-04449913 in combination with low dose ARA-C (LDAC)

干预措施: PF-04449913 (Drug)

Arm A (Phase 1B)

Experimental

PF-04449913 in combination with low dose ARA-C (LDAC)

干预措施: Low dose ARA-C (LDAC) (Drug)

Arm B (Phase 1B)

Experimental

PF-04449913 in combination with Decitabine

干预措施: PF-04449913 (Drug)

Arm B (Phase 1B)

Experimental

PF-04449913 in combination with Decitabine

干预措施: Decitabine (Drug)

Arm C (Phase 1B)

Experimental

PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.

干预措施: PF-04449913 (Drug)

Arm C (Phase 1B)

Experimental

PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.

干预措施: Daunorubicin (Drug)

Arm C (Phase 1B)

Experimental

PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.

干预措施: Cytarabine (Drug)

P2 Fit (Phase 2 Single Arm)

Experimental

PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.

干预措施: PF-04449913 (Drug)

P2 Fit (Phase 2 Single Arm)

Experimental

PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.

干预措施: Daunorubicin (Drug)

P2 Fit (Phase 2 Single Arm)

Experimental

PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.

干预措施: Cytarabine (Drug)

P2 Unfit (Phase 2 Randomized)

Other

Patients will be randomized 2:1 (low dose ARA-C in combination with PF-04449913: low dose ARA-C alone).

干预措施: PF-04449913 (Drug)

P2 Unfit (Phase 2 Randomized)

Other

Patients will be randomized 2:1 (low dose ARA-C in combination with PF-04449913: low dose ARA-C alone).

干预措施: Low dose ARA-C (LDAC) (Drug)

结局指标

主要结局

Number of Participants With Dose-limiting Toxicities (DLTs) at Phase 1B

时间窗: Arms A and B: Cycle 1, Day 1 to Day 28; Arm C: Cycle 1, Day -3 to Day 21 or to Day 28 depending on when the next chemotherapy cycle was started

A DLT was any of the following adverse events (AEs) in Cycle 1 and considered by the investigator possibly related to glasdegib in combination with chemotherapy: (1) Grade \>= 3 non-hematologic toxicity, excluding Grade \>= 3 infection, fever (including febrile neutropenia), infusion related AEs, electrolyte abnormalities and ALT/AST elevation that returned to Grade \<= 1 or baseline within 7 days; (2) prolonged myelosuppression that lasted longer than 42 days from the point of detection, defined as absolute neutrophil count (ANC) \< 500/microliter(mcL) or platelet count \< 10 \*10\^9/L with a normal bone marrow (\<5% blasts and no evidence of disease or dysplasia); (3) inability to deliver at least 80% of the planned study doses for all agents in a combination due to non-hematologic toxicities; (4) Delay of \>28 days in receiving the next scheduled cycle due to persisting non-hematologic toxicities. Arm A: Glasdegib+LDAC; Arm B: Glasdegib+Decitabine; Arm C: Glasdegib+Cytarabine/Daunorubicin.

Percentage of Participants With Complete Response (CR) at Phase 2 Fit

时间窗: 4 years

For AML participants:CR were those with repeat bone marrow showing \<5% myeloblasts,spicules present and no Auer rods, peripheral blood showing neutrophils\>=1000/mcL and platelets\>=100,000/mcL, transfusion independent and no extramedullary disease. For MDS participants:CR were those with repeat bone marrow showing \<=5% myeloblasts, peripheral blood showing neutrophils\>=1000/mcL, platelets\>=100,000/mcL, 0% blast and hemoglobin (Hgb)\>= 11 g/dL, normal maturation of all cell lines.

Overall Survival (OS) at Phase 2 Unfit

时间窗: Randomization to Follow-up (4 years)

OS was defined as duration from the date of randomization to the date of death from any cause. Kaplan-Meier (KM) method was used to estimate median OS. In this method, every participant had a follow-up time which was associated with an indicator, 1=event (death in our case), and 0 =censored. If the participants were not known to have died, time to date of last known to be alive was used as to calculate the follow-up time and indicator was 0 for these participants. KM method estimates the median OS based on the K-M curve. The K-M curve only drops when we had an event and censor data are the ticks in the graph. To estimate median OS, the K-M curve usually will be smoothed first and a line will be drawn at 50%. The median OS is the point when K-M curve and the horizontal hit. Survival status was collected every month for the first 2 months after discontinuation of study treatment and thereafter every 2 months until death or 4 years from time of randomization for each participant.

次要结局

  • Overall Survival (OS) at Phase 1B(First dose to Follow-up (4 years))
  • Overall Survival (OS) at Phase 2 Fit(First dose to Follow-up (4 years))
  • Percentage of Participants With CR / Complete Response With Incomplete Blood Count Recovery (CRi) at Phase 1B(4 years)
  • Percentage of Participants With Complete Response (CR) at Phase 2 Unfit(4 years)
  • Percentage of Participants With Disease-specific Efficacy for Acute Myeloid Leukemia (AML) at Phase 2 Fit and Unfit(4 years)
  • Tmax of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10(Pre-dose, 0.5, 1, 6 and 24 hours post-dose on Induction Cycle 1/Day 3; pre-dose, 0.5, 1, 4, 6 and 24 hours post-dose on Induction Cycle 1/Day 10)
  • Percentage of Participants With Disease-specific Efficacy for Myelodysplastic Syndrome (MDS) at Phase 2 Fit and Unfit(4 years)
  • Maximum Observed Plasma Concentration (Cmax) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21(Pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post-dose on Cycle 1/Day 10 and Cycle 1/Day 21)
  • Time to Cmax (Tmax) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21(Pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post-dose on Cycle 1/Day 10 and Cycle 1/Day 21)
  • Area Under the Plasma Concentration-time Profile From Time 0 to Dosing Interval (AUCtau) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21(Pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post-dose on Cycle 1/Day 10 and Cycle 1/Day 21)
  • Cmax of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1(Pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post-dose on Cycle 1/Day 10; pre-dose, 0.5, 1, 2, 6 and 24 hours post-dose on Cycle 2/Day 1)
  • Tmax of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1(Pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post-dose on Cycle 1/Day 10; pre-dose, 0.5, 1, 2, 6 and 24 hours post-dose on Cycle 2/Day 1)
  • AUCtau of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1(Pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post-dose on Cycle 1/Day 10; pre-dose, 0.5, 1, 2, 6 and 24 hours post-dose on Cycle 2/Day 1)
  • Cmax of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10(Pre-dose, 0.5, 1, 6 and 24 hours post-dose on Induction Cycle 1/Day 3; pre-dose, 0.5, 1, 4, 6 and 24 hours post-dose on Induction Cycle 1/Day 10)
  • AUCtau of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10(Pre-dose, 0.5, 1, 6 and 24 hours post-dose on Induction Cycle 1/Day 3; pre-dose, 0.5, 1, 4, 6 and 24 hours post-dose on Induction Cycle 1/Day 10)
  • Cmax of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10(Pre-dose, 0.25, 0.5, 1, 2, 4 and 6 hours post-dose on Cycle 1/Day 2 and Cycle 1/Day 10)
  • Tmax of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10(Pre-dose, 0.25, 0.5, 1, 2, 4 and 6 hours post-dose on Cycle 1/Day 2 and Cycle 1/Day 10)
  • Area Under the Plasma Concentration-time Profile From Time 0 to Infinity (AUCinf) of LDAC in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10(Pre-dose, 0.25, 0.5, 1, 2, 4 and 6 hours post-dose on Cycle 1/Day 2 and Cycle 1/Day 10)
  • Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10(Pre-dose, 0.25, 0.5, 1, 2, 4 and 6 hours post-dose on Cycle 1/Day 2 and Cycle 1/Day 10)
  • Cmax of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2(Pre-dose, 0.5 hour from start of infusion, 1 hour (at end of infusion) and 2, 3 and 4 hours from start of infusion on Cycle 1/Day 1 and Cycle 1/Day 2)
  • Tmax of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2(Pre-dose, 0.5 hour from start of infusion, 1 hour (at end of infusion) and 2, 3 and 4 hours from start of infusion on Cycle 1/Day 1 and Cycle 1/Day 2)
  • AUCinf of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2(Pre-dose, 0.5 hour from start of infusion, 1 hour (at end of infusion) and 2, 3 and 4 hours from start of infusion on Cycle 1/Day 1 and Cycle 1/Day 2)
  • AUCtau of Cytarabine and Ara-U in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3(Pre-dose, 6 and 24 hours post start of cytarabine infusion on Induction Cycle 1/Day 3)
  • Cmax of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3(Pre-dose, 0.25, 0.5, 1, 4, 6, 24 hours post administration of daunorubicin on Induction Cycle 1/Day 3)
  • Tmax of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3(Pre-dose, 0.25, 0.5, 1, 4, 6, 24 hours post administration of daunorubicin on Induction Cycle 1/Day 3)
  • AUCtau of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3(Pre-dose, 0.25, 0.5, 1, 4, 6, 24 hours post administration of daunorubicin on Induction Cycle 1/Day 3)
  • Pre-dose Plasma Concentration (Ctrough) of Glasdegib in Phase 2 Fit on Induction Cycle 1/Day 10(Pre-dose, 1 and 4 hours post-dose on Induction Cycle 1/Day 10)
  • Cmax of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10(Pre-dose, 1, 2, 4, and 6 hour post-dose on Cycle 1/Day 10)
  • Tmax of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10(Pre-dose, 1, 2, 4, and 6 hour post-dose on Cycle 1/Day 10)
  • AUCtau of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10(Pre-dose, 1, 2, 4, and 6 hour post-dose on Cycle 1/Day 10)
  • Number of Participants With Disease-related Gene Mutations at Phase 1B(Baseline (Cycle 1/Day 1 pre-dose for Glasdegib + LDAC and Glasdegib + Decitabine Arms; Induction Cycle 1/Day -3 pre-dose for Glasdegib +Cytarabine/Daunorubicin Arm))
  • Serum Levels of Circulating Protein Analytes at Phase 1B - Baseline(Baseline (Induction Cycle 1/Day -3 pre-dose))
  • Serum Levels of Circulating Protein Analytes at Phase 1B - Induction Cycle 1/Day 3(Induction Cycle 1/Day 3, 1 Hour Post dose)
  • Serum Levels of Circulating Protein Analytes at Phase 1B - Induction Cycle 1/Day 10(Induction Cycle 1/Day 10, 1 Hour Post dose)
  • Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B(Baseline (Cycle 1/Day 1 pre-dose for Glasdegib + LDAC and Glasdegib + Decitabine Arms; Induction Cycle 1/Day -3 pre-dose for Glasdegib +Cytarabine/Daunorubicin Arm))
  • Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B - Induction Cycle 1/Lead-In(Induction Cycle 1/Lead-in, 1 Hour Post dose)
  • Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B - Induction Cycle 1/Day 3(Induction Cycle 1/Day 3, 1 Hour Post dose)
  • Number of Participants With Disease-related Gene Mutations at Phase 2 Fit and Unfit(Baseline (Induction Cycle 1/Day -3 pre-dose for Phase 2 Fit; Cycle 1/Day 1 pre-dose for Phase 2 Unfit))
  • Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Induction Cycle 1/Day 3(Induction Cycle 1/Day 3, 1 Hour Post dose)
  • Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Induction Cycle 1/Day 10(Induction Cycle 1/Day 10, 1 Hour Post dose)
  • Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Consolidation Cycle 1/Day 1(Consolidation Cycle 1/Day 1, 1 Hour Post dose)
  • Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Consolidation Cycle 1/Day 10(Consolidation Cycle 1/Day 10, Pre-dose)
  • Serum Levels of Circulating Protein Analytes at Phase 2 Fit - End of Treatment(End of Treatment (maximum of 12 cycles from start of therapy or until disease progression or relapse, participant refusal or unacceptable toxicity occurred, whichever came first, an average of 1 year))
  • Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit(Baseline (Induction Cycle 1/Day -3 pre-dose))
  • Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - Induction Cycle 1/Day 3(Induction Cycle 1/Day 3, 1 Hour Post dose)
  • Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - Induction Cycle 1/Day 10(Induction Cycle 1/Day 10, 1 Hour Post dose)
  • Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - End of Treatment(End of Treatment (maximum of 12 cycles from start of therapy or until disease progression or relapse, participant refusal or unacceptable toxicity occurred, whichever came first, an average of 1 year))
  • Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 1(Cycle 1/Day 1, 1 Hour Post dose)
  • Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit - Cycle 1/Day 1(Cycle 1/Day 1, 1 Hour Post-dose)
  • Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit - End of Treatment(End of Treatment (maximum of 12 cycles from start of therapy or until disease progression or relapse, participant refusal or unacceptable toxicity occurred, whichever came first, an average of 1 year))
  • Baseline mRNA Levels Associated With Best Overall Response at Phase 2 Fit(Baseline (Induction Cycle 1/Day -3 pre-dose))
  • Baseline mRNA Levels Associated With Best Overall Response at Phase 2 Unfit(Baseline (Cycle 1/Day 1 pre-dose))
  • Number of Participants With Corrected QT Interval Using Fridericia's Formula (QTcF) Values Meeting Predefined Criteria at Phase 2 Fit and Unfit(1 year)
  • Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 10(Cycle 1/Day 10, Pre-dose)
  • Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit(Baseline (Cycle 1/Day 1 pre-dose))
  • Ratios of mRNA Levels to Baseline at Phase 2 Fit - Induction Cycle 1/Day 3(Baseline (Induction Cycle 1/Day -3 pre-dose); Induction Cycle 1/Day 3, 1 Hour Post dose)
  • Ratios of mRNA Levels to Baseline at Phase 2 Fit - End of Treatment(Baseline (Induction Cycle 1/Day -3 pre-dose); End of Treatment (maximum of 12 cycles from start of therapy or until disease progression or relapse, participant refusal or unacceptable toxicity occurred, whichever came first, an average of 1 year))
  • Ratios of mRNA Levels to Baseline at Phase 2 Unfit - End of Treatment(Baseline (Cycle 1/Day 1 pre-dose); End of Treatment (maximum of 12 cycles from start of therapy or until disease progression or relapse, participant refusal or unacceptable toxicity occurred, whichever came first, an average of 1 year))
  • Number of Participants With Treatment-emergent Adverse Events (AEs) at Phase 1B (All Causality)(4 years)
  • Number of Participants With Treatment-emergent AEs at Phase 1B (Treatment-related)(4 years)
  • Ratios of mRNA Levels to Baseline Associated With Best Overall Response at Phase 2 Fit(Baseline (Induction Cycle 1/Day -3 pre-dose); End of Treatment (maximum of 12 cycles from start of therapy or until disease progression or relapse, participant refusal or unacceptable toxicity occurred, whichever came first, an average of 1 year))
  • Number of Participants With Corrected QT Interval Using Fridericia's Formula (QTcF) Values Meeting Predefined Criteria at Phase 1B(1 year)
  • Ratios of mRNA Levels Associated With Best Overall Response at Phase 2 Unfit(Baseline (Cycle 1/Day 1 pre-dose); Cycle 1/Day 1, 1 Hour Post dose)
  • Number of Participants With Treatment-emergent AEs at Phase 2 Fit and Unfit (All Causality)(4 years)
  • Number of Participants With Treatment-emergent AEs Categorized by Seriousness at Phase 1B(4 years)
  • Number of Participants With Treatment-emergent AEs at Phase 2 Fit and Unfit (Treatment-related)(4 years)
  • Number of Participants With Treatment-emergent AEs Categorized by Seriousness at Phase 2 Fit and Unfit(4 years)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (78)

Loading locations...

相似试验

已完成
2 期
PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell TransplantAdult Acute Myeloid Leukemia in RemissionRecurrent Adult Acute Myeloid Leukemia
NCT01841333University of Colorado, Denver31
已完成
2 期
A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid ArthritisRheumatoid Arthritis
NCT00938587Pfizer86
招募中
1 期
AB8939 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaAcute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseMyelodysplastic Syndrome Acute Myeloid Leukemia
NCT05211570AB Science78
已完成
不适用
A study to detect the effect of radiofrequent ablation in combination with ipilimumab in patients with eye melanoma that spread out to the liver.uveal melanomaliver metastasesoog melanoomlever metastasen
NL-OMON26122KI-AV44
招募中
1 期
A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian CancerSolid Tumor, Adult
NCT06232863Zhuhai Beihai Biotech Co., Ltd24